Wall Street analysts expect that Repligen Co. (NASDAQ:RGEN) will report earnings per share of $0.12 for the current quarter, Zacks reports. Five analysts have provided estimates for Repligen’s earnings. The lowest EPS estimate is $0.11 and the highest is $0.13. Repligen posted earnings of $0.08 per share in the same quarter last year, which indicates a positive year over year growth rate of 50%. The business is expected to issue its next earnings report on Wednesday, February 28th.

According to Zacks, analysts expect that Repligen will report full year earnings of $0.61 per share for the current year, with EPS estimates ranging from $0.60 to $0.63. For the next year, analysts forecast that the business will report earnings of $0.71 per share, with EPS estimates ranging from $0.68 to $0.75. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Repligen.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, November 9th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.04. The company had revenue of $36.58 million during the quarter, compared to the consensus estimate of $35.69 million. Repligen had a return on equity of 7.57% and a net margin of 16.93%. Repligen’s quarterly revenue was up 48.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.08 earnings per share.

Several research analysts have recently issued reports on RGEN shares. Jefferies Group reaffirmed a “hold” rating and set a $40.00 price target on shares of Repligen in a research note on Thursday, September 14th. Stephens reaffirmed an “overweight” rating and set a $50.00 price target on shares of Repligen in a research note on Tuesday, September 26th. First Analysis raised Repligen from an “equal weight” rating to an “overweight” rating and set a $47.00 price target for the company in a research note on Monday, October 2nd. Zacks Investment Research raised Repligen from a “hold” rating to a “buy” rating and set a $43.00 price target for the company in a research note on Thursday, October 5th. Finally, CL King started coverage on Repligen in a research note on Monday, November 13th. They set a “buy” rating and a $41.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $44.38.

In related news, VP Howard Benjamin sold 12,729 shares of the business’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $35.34, for a total value of $449,842.86. Following the completion of the transaction, the vice president now owns 36,554 shares of the company’s stock, valued at approximately $1,291,818.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.50% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of RGEN. First Trust Advisors LP grew its holdings in Repligen by 85.5% in the 2nd quarter. First Trust Advisors LP now owns 39,036 shares of the biotechnology company’s stock valued at $1,618,000 after buying an additional 17,996 shares during the period. Bank of New York Mellon Corp grew its holdings in Repligen by 3.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 451,927 shares of the biotechnology company’s stock valued at $18,728,000 after buying an additional 15,241 shares during the period. Legal & General Group Plc grew its holdings in Repligen by 15.3% in the 2nd quarter. Legal & General Group Plc now owns 68,677 shares of the biotechnology company’s stock valued at $2,845,000 after buying an additional 9,121 shares during the period. BNP Paribas Arbitrage SA grew its holdings in shares of Repligen by 56.9% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 10,162 shares of the biotechnology company’s stock worth $421,000 after purchasing an additional 3,687 shares during the period. Finally, Victory Capital Management Inc. grew its holdings in shares of Repligen by 17.7% during the 2nd quarter. Victory Capital Management Inc. now owns 4,001 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 601 shares during the period. Institutional investors own 82.50% of the company’s stock.

Repligen (NASDAQ RGEN) opened at $37.13 on Monday. The stock has a market capitalization of $1,620.00, a price-to-earnings ratio of 62.93, a PEG ratio of 2.08 and a beta of 1.04. Repligen has a one year low of $28.48 and a one year high of $46.81.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/08/zacks-brokerages-anticipate-repligen-co-rgen-to-post-0-12-earnings-per-share.html.

Repligen Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Get a free copy of the Zacks research report on Repligen (RGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.